Catabasis Pharmaceuticals (NASDAQ:CATB) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday, February 4th.
CATB has been the subject of several other research reports. Zacks Investment Research lowered Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. Wedbush set a $28.00 price objective on Catabasis Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, January 29th. Finally, Oppenheimer lifted their price objective on Catabasis Pharmaceuticals from $7.00 to $77.00 and gave the company an “outperform” rating in a research note on Monday, January 14th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $31.38.
NASDAQ:CATB traded up $0.08 during trading hours on Monday, hitting $4.90. 65,396 shares of the company’s stock traded hands, compared to its average volume of 205,686. The firm has a market capitalization of $35.00 million, a price-to-earnings ratio of -0.39 and a beta of 1.75. Catabasis Pharmaceuticals has a 52 week low of $3.60 and a 52 week high of $21.80.
A hedge fund recently raised its stake in Catabasis Pharmaceuticals stock. Oppenheimer & Co. Inc. grew its position in shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) by 156.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 508,415 shares of the biotechnology company’s stock after purchasing an additional 310,415 shares during the period. Oppenheimer & Co. Inc. owned about 0.72% of Catabasis Pharmaceuticals worth $407,000 at the end of the most recent reporting period.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases.
Read More: What is systematic risk?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.